Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis

Genome Therapeutics Corp. and ICAgen, Inc. have announced an agreement that utilizes Genome Therapeutics’ technology to facilitate the assessment and development of a clinical trial design protocol for one of ICAgen’s ion channel targets.

The genomics technology utilizes polymorphism analysis in subgroups of the target patient population to rapidly determine the target’s efficacy and thus quickly assess its likelihood for clinical success.

The ion channel target under analysis belongs to an attractive class of therapeutic targets that play a critical role in regulating the flow of electrolytes, such as potassium, sodium and calcium, in and out of cells.

As part of this pharmacogenomics collaboration, Genome Therapeutics will use its proprietary sequence-based polymorphism detection platform to analyze inter-individual variation and determine genetic polymorphisms which could impact protein structure and function.

This technology allows the identification of SNPs (single nucleotide polymorphisms), as well as deletions, insertions or re- arrangements in the gene region.

Genome Therapeutics will also develop a unique detection system for the drug target, which will be used to perform rapid sequence analysis of the essential regions of the gene using genomic DNA from a statistically relevant panel of individuals.

This analysis will help in understanding the relationship of genetic polymorphisms to specific drug efficacy and increase the potential for clinical success.

“It has become essential to consider human variation and individuality in all drug development efforts – from target selection through clinical development of new products,” said Dr. Richard D. Gill, President and Chief Operating Officer of Genome Therapeutics.

clearly appreciates the benefits of utilizing genomics for early target analysis to help mitigate the risks associated with clinical trial design.”

“We welcome the opportunity to collaborate with Genome Therapeutics and believe that the quality of their work will ensure the detection and accuracy of genetic variations and will continue to increase the probability of ICAgen’s pharmaceutical success,” said P. Kay Wagoner, Ph.D., President and CEO of ICAgen.

“As a rapidly- growing biopharmaceutical company with multiple opportunities for clinical development, we will utilize technologies that can increase the efficiency of clinical development and accelerate or refine the clinical trial process.”

This collaboration is an early application of Genome Therapeutics’ broad array of genomics-based tools and technologies employed in its pharmacogenomics business, which can be used in collaboration with all sizes of pharmaceutical companies to improve the efficiency of their drug discovery programs, from target selection through clinical trial design and trial repositioning, to rescuing post-marketing product failures.

Reviews

dragon-pharmaceutical
Dragon Pharma operates four separate pharmacy businesses from its location in Europe. They offer in-store and mail order steroids: Trenbolone 100.

Buying Dragon Pharmaceuticals Legally

Trenbolone 200

Injectable Anabolic Steroid
Principal Component: Trenbolone Enanthate
Branded by: Dragon Pharmaceuticals
Amount: 1 X 10 ml (200 mg/ml)

Clenbuterol - Discount Price

Administration: Oral
Basal Constituent: Clenbuterol Hydrochloride
Made by: Dragon Pharma LLC
Pack: 30 x 100 tablets (40 mcg/pastille)
Price: 30 x $20

Enantat 250 - Bulk Price

Administration: Injection
Primary Substance: Testosterone Enanthate
Producer: Dragon Pharmaceutical
Package: 10 x 10 mL vial (250 mg/mL)
Price: 10 x $36.00

Cypionat 250 - Bulk Price

Administration: Injection
Basal Substance: Testosterone Cypionate
Branded by: Dragon Pharmaceuticals
Pack: 10 x 10 mL vial (250 mg/mL)
Price: 10 x $36.00

Cypionat 250

Injectable Steroid for Muscle Growth
Prime Component: Testosterone Cypionate
Branded by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (250 mg/mL)

Masteron 200 [10 Vials]

Injectable Steroid for Muscle Growth
Active Constituent: Drostanolone Enanthate
Manufacturer: Dragon Pharma
10 Vials [10 mL per Vial (200 mg/ml)]
Price: 10 x $67.00 = $670.00 in Total

Enantat 400

Principal Ingredient: Testosterone Enanthate
Made by: Dragon Pharma Labs
Pack: 10 mL vial (400 mg/mL)

Suspension 100

Basal Ingredient: Testosterone Suspension
Producer: Dragon Pharmaceutical
Unit: 10 mL vial (100 mg/mL)

Primobolan 100

Main Ingredient: Methenolone Enanthate
Made by: Dragon Pharma LLC
Pack: 10 mL vial (100 mg/mL)

Turanabol

Prime Component: Chlorodehydromethyltestosterone
Branded by: Dragon Pharmaceuticals
Pack: 100 pills (10 mg/pastille)

Nolvadex

Base Substance: Tamoxifen Citrate
Made by: Dragon Pharmaceutical
Pack: 100 tabs (20 mg/tablet)

NPP 150

Basal Component: Nandrolone Phenylpropionate
Producer: Dragon Pharma LLC
Unit: 10 x 10 mL vial (150 mg/mL)